List view / Grid view
Rapid progress in digital health technologies is enriching clinical trial design, improving clinical trial recruitment strategies and harnessing the power of clinical trial data to improve outcomes for patients and guide future research. Here, Natalie Fishburn, Cristina Duran and Serban Ghiorghiu, from R&D at AstraZeneca, discuss the evolving nature of clinical innovation…
A total of five drugs were recommended for approval at the CHMP’s December meeting, including a gene therapy and two cancer drugs.
An early halt has been called to a major kidney drug trial following positive results for patients with chronic kidney disease (CKD).
Forxiga’s approval, based on unprecedented Phase III data, is the most significant advancement in chronic kidney disease (CKD) treatment in over 20 years.
Ziltivekimab was found to reduce inflammatory biomarkers of atherosclerosis by up to 93 percent in patients with chronic kidney disease and high cardiovascular risk.
In a bid to address an unmet clinical need for patients in Japan, roxadustat has been presented as a potential treatment for a particular kind of anaemia.
Fast Track designation has been granted to Farxiga to prevent heart and kidney failure in patients with chronic kidney disease.
Results of a study suggest the need for caution in the prescription of direct oral anticoagulants for patients with chronic kidney disease, due to the risk of bleeding...
Researchers translate neuroimaging tools to study renal fibrosis...
